182347-24-6

Basic information

• Product Name: Ethanol, 2-(2-azidoethoxy)-, 4-methylbenzenesulfonate (ester)
• CAS NO: 182347-24-6
• Molecular Formula: C11H15N3O4S
• Molecular Weight: 285.324
• Mol File: 182347-24-6.mol
• Article Data: 28

Chemical Properties

• CAS DataBase Reference: Ethanol, 2-(2-azidoethoxy)-, 4-methylbenzenesulfonate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanol, 2-(2-azidoethoxy)-, 4-methylbenzenesulfonate (ester)(182347-24-6)
• EPA Substance Registry System: Ethanol, 2-(2-azidoethoxy)-, 4-methylbenzenesulfonate (ester)(182347-24-6)

Safety Data

• Hazardous Substances Data: 182347-24-6(Hazardous Substances Data)

Upstream product

• 118591-58-5 5-tosyloxy-3-oxapentanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 139115-90-5 2-(2-azidoethoxy)ethanol 
• 7460-82-4 diethylene glycol ditosylate 

Downstream Products

• 1246850-63-4 1,3-bis(2-(2-azidoethoxy)ethoxy)benzene 
• 1033617-47-8 p-(2-azidoethoxyethoxy)-N-(2-benzyloxyacetyl)aniline 
• 182347-26-8 methyl 3,5-bis-[2-(2-azidoethoxy)ethoxy]benzoate 

Relevant articles and documents

Development of a multifunctional aminoxy-based fluorescent linker for glycan immobilization and analysis

Glycan arrays have become a technique of choice to screen glycan-protein interactions in a highthroughput manner with high sensitivity and low sample consumption. Here, the synthesis of a new multifunctional fluorescent linker for glycan labeling via amin

Compound for degrading TGF-beta1 through targeted ubiquitination, and preparation method and application thereof

The invention discloses a compound (I) for targeted ubiquitination degradation of TGF-beta1. The compound (I) for degradation of TGF-beta1 through targeted ubiquitination is formed by connecting a TGF-beta1 micromolecular ligand and an E3 ubiquitin ligase

Preparation method of target BTK protein degradation compound, and application of compound in treating autoimmune diseases and tumors

The invention provides a compound, the compound is a compound represented by a formula I, and a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceuticallyacceptable salt and prodrug of the compound represented by the formula I. The compound has a strong degradation effect on wild-type BTK, has no inhibition or degradation effects on other targets suchas EGFR, ITK, TEC, and the like, and has an effect of specific targeted degradation of BTK proteins. The formula I is X-Y-Z.